Clinical-trial update on a novel experimental therapy for people with previously treated myelofibrosis, previewing data to be presented at a major hematology meeting.
Key Takeaways
- Phase 1 AJX-101 trial enrolled 23 previously treated myelofibrosis patients across five dose levels
- Both SVR35 and TSS50 response rates were 70% in treated patients
- VAF reductions occurred in 21 of 23 patients, and 35% had ≥50% reductions at week 24